Memantine Drug Classification
Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist with low to moderate affinity, characterized by voltage-dependent blockade and fast on/off kinetics. 1
Mechanism of Action
Memantine functions as a voltage-dependent, open-channel NMDA receptor blocker that preferentially binds to NMDA receptor-operated cation channels during pathological overstimulation while allowing normal physiological neurotransmission to occur. 1, 2
The drug blocks excessive calcium influx induced by chronic overstimulation of NMDA receptors, which is thought to contribute to neuronal damage in Alzheimer's disease. 3, 2
Memantine's therapeutic utility stems from its moderate affinity and rapid blocking/unblocking kinetics, which distinguish it from other NMDA antagonists like ketamine that cause serious adverse effects. 4, 5
Receptor Selectivity Profile
Memantine shows low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine, and glycine receptors, as well as voltage-dependent calcium, sodium, or potassium channels. 1
The drug demonstrates antagonistic effects at 5HT3 receptors with potency similar to NMDA receptors, and blocks nicotinic acetylcholine receptors with one-sixth to one-tenth the potency. 1
Memantine does not inhibit acetylcholinesterase, allowing safe combination with cholinesterase inhibitors like donepezil without pharmacodynamic interference. 1
Clinical Classification Context
The FDA classifies memantine as an NMDA receptor antagonist approved specifically for moderate-to-severe Alzheimer's disease. 6, 1, 7
This distinguishes memantine from the other major drug class used in Alzheimer's disease—cholinesterase inhibitors (donepezil, rivastigmine, galantamine)—which work through an entirely different mechanism. 8, 7
Memantine represents the only approved NMDA antagonist for dementia treatment, making it a unique pharmacological option in this therapeutic category. 3, 5